In Vitro Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory Pathogen.
There has been an increase in the number of pertussis cases reported since the introduction of the acellular pertussis vaccine. While children that present with pertussis have a characteristic whooping cough, adults can simply have a persistent, nonspecific cough and remain undiagnosed. Macrolide antibiotics, such as azithromycin, are the currently recommended treatment for pertussis. Solithromycin is a new macrolide and the first fluoroketolide with broad activity against a wide spectrum of bacterial pathogens and has completed clinical development for community-acquired bacterial pneumonia. This study reports the potent in vitro activity of solithromycin against a collection of recent isolates of Bordetella pertussis.
Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA Dwight_Hardy@urmc.rochester.edu.
Dwight J
DJ
Hardy
Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.
David
D
Vicino
Cempra, Inc., Chapel Hill, North Carolina, USA.
Prabhavathi
P
Fernandes
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001886:Bordetella pertussis / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D018942:Macrolides / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D014230:Triazoles / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D018942:Macrolides; D014230:Triazoles; C547755:solithromycin